476 related articles for article (PubMed ID: 10739374)
1. Outpatient treatment of pulmonary embolism with dalteparin.
Kovacs MJ; Anderson D; Morrow B; Gray L; Touchie D; Wells PS
Thromb Haemost; 2000 Feb; 83(2):209-11. PubMed ID: 10739374
[TBL] [Abstract][Full Text] [Related]
2. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
3. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: a comparison of patient self-injection with homecare injection.
Wells PS; Kovacs MJ; Bormanis J; Forgie MA; Goudie D; Morrow B; Kovacs J
Arch Intern Med; 1998 Sep; 158(16):1809-12. PubMed ID: 9738611
[TBL] [Abstract][Full Text] [Related]
4. Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity.
Savage KJ; Wells PS; Schulz V; Goudie D; Morrow B; Cruickshank M; Kovacs MJ
Thromb Haemost; 1999 Sep; 82(3):1008-10. PubMed ID: 10494754
[TBL] [Abstract][Full Text] [Related]
5. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Couturaud F; Julian JA; Kearon C
Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355
[TBL] [Abstract][Full Text] [Related]
6. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism.
Wells PS; Forgie MA; Simms M; Greene A; Touchie D; Lewis G; Anderson J; Rodger MA
Arch Intern Med; 2003 Apr; 163(8):917-20. PubMed ID: 12719200
[TBL] [Abstract][Full Text] [Related]
7. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
[TBL] [Abstract][Full Text] [Related]
8. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin.
Kovacs MJ; Kearon C; Rodger M; Anderson DR; Turpie AG; Bates SM; Desjardins L; Douketis J; Kahn SR; Solymoss S; Wells PS
Circulation; 2004 Sep; 110(12):1658-63. PubMed ID: 15364803
[TBL] [Abstract][Full Text] [Related]
9. Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
DeBernardo RL; Perkins RB; Littell RD; Krasner CN; Duska LR
Obstet Gynecol; 2005 May; 105(5 Pt 1):1006-11. PubMed ID: 15863537
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous low-molecular-weight heparin fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study.
Meyer G; Brenot F; Pacouret G; Simonneau G; Gillet Juvin K; Charbonnier B; Sors H
Thromb Haemost; 1995 Dec; 74(6):1432-5. PubMed ID: 8772215
[TBL] [Abstract][Full Text] [Related]
11. The Janus face of thromboprophylaxis in patients with high risk for both thrombosis and bleeding during intracranial surgery: report of five exemplary cases.
Niemi T; Silvasti-Lundell M; Armstrong E; Hernesniemi J
Acta Neurochir (Wien); 2009 Oct; 151(10):1289-94. PubMed ID: 19513580
[TBL] [Abstract][Full Text] [Related]
12. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
Wells PS; Anderson DR; Rodger MA; Forgie MA; Florack P; Touchie D; Morrow B; Gray L; O'Rourke K; Wells G; Kovacs J; Kovacs MJ
Arch Intern Med; 2005 Apr; 165(7):733-8. PubMed ID: 15824291
[TBL] [Abstract][Full Text] [Related]
13. Dalteparin: new indication. Prophylaxis in medical patients: no advance.
Prescrire Int; 2005 Feb; 14(75):14-5. PubMed ID: 15751168
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen.
Douketis JD; Johnson JA; Turpie AG
Arch Intern Med; 2004 Jun; 164(12):1319-26. PubMed ID: 15226166
[TBL] [Abstract][Full Text] [Related]
15. Outpatient treatment of community acquired venous thromboembolism--the Christchurch experience.
Heaton D; Han DY; Inder A
N Z Med J; 2002 Jul; 115(1158):U105. PubMed ID: 12362180
[TBL] [Abstract][Full Text] [Related]
16. Outpatient treatment of patients with pulmonary embolism.
Wells PS; Büller HR
Semin Vasc Med; 2001 Nov; 1(2):229-34. PubMed ID: 15199507
[TBL] [Abstract][Full Text] [Related]
17. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
Sarasin FP; Bounameaux H
Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
[TBL] [Abstract][Full Text] [Related]
18. Dalteparin versus unfractionated heparin in critically ill patients.
; Cook D; Meade M; Guyatt G; Walter S; Heels-Ansdell D; Warkentin TE; Zytaruk N; Crowther M; Geerts W; Cooper DJ; Vallance S; Qushmaq I; Rocha M; Berwanger O; Vlahakis NE
N Engl J Med; 2011 Apr; 364(14):1305-14. PubMed ID: 21417952
[TBL] [Abstract][Full Text] [Related]
19. Home treatment of deep vein thrombosis: a two-years experience of a single institution.
Grau E; Real E; Pastor E; Viciano V; Aguiló J
Haematologica; 1998 May; 83(5):438-41. PubMed ID: 9658729
[TBL] [Abstract][Full Text] [Related]
20. [Outpatient treatment of deep vein thrombosis with low-molecular-weight heparins. Experience from an open, prospective study in daily practice].
Heidenreich C; Hohmann V; Bramlage P
Med Klin (Munich); 2009 Jan; 104(1):20-7. PubMed ID: 19142593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
